ALX Oncology Announces November 2020 Virtual Investor Conference Participation

Rhea-AI Summary

ALX Oncology Holdings Inc. (Nasdaq: ALXO) announced participation in two upcoming virtual investor conferences. CEO Jaume Pons and senior executives will engage in fireside chats at the 29th Annual Credit Suisse Virtual Healthcare Conference on November 9 and the Jefferies Virtual London Healthcare Conference on November 19. ALX Oncology is focused on developing therapies that inhibit the CD47 checkpoint pathway, with its lead product candidate, ALX148, showing promising clinical results against various cancers. Webcast links are provided for interested investors.

Positive

• Participation in two reputable virtual investor conferences may enhance visibility and investor interest.
• ALX148 shows promising clinical responses in various malignancies, indicating potential for future growth.

Negative

• None.

BURLINGAME, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer and other senior executives, will participate in two virtual investor conferences in November.

29^th Annual Credit Suisse Virtual Healthcare Conference
Format: Fireside chat with covering analyst, Martin Auster, M.D.
Date: Monday, November 9
Time: 11:45 AM Eastern Time
Webcast link: Available here

Jefferies Virtual London Healthcare Conference
Format: Fireside chat with covering analyst, Michael Yee
Date: Thursday, November 19
Time: 1:10 PM Eastern Time
Webcast link: Available here

A live webcast of the fireside chats can be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com and selecting the Investor Calendar under the News and Events tab. A replay of the webcasts will be archived for up to 90 days following the presentation dates.

About ALX Oncology

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. ALX148 has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of ALX148 for the treatment of a range of solid tumor indications and myelodysplastic syndromes. For more information, please visit ALX Oncology’s website at https://www.alxoncology.com.

 

FAQ

What is ALX Oncology's lead product candidate?

ALX Oncology's lead product candidate is ALX148, a next generation CD47 blocking therapeutic.

When is the Credit Suisse Virtual Healthcare Conference?

The Credit Suisse Virtual Healthcare Conference is on November 9, 2020.

What will be discussed at the Jefferies Virtual London Healthcare Conference?

The Jefferies Virtual London Healthcare Conference will feature a fireside chat with ALX Oncology's executives.

What is the significance of the CD47 checkpoint pathway?

The CD47 checkpoint pathway is important in immuno-oncology as it plays a role in how the immune system interacts with cancer cells.